



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number : **0 393 890 B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification :
12.08.92 Bulletin 92/33

(51) Int. Cl.⁵ : **A61K 31/71, A61K 9/00,
A61K 47/14, A61K 47/44**

(21) Application number : **90303716.6**

(22) Date of filing : **06.04.90**

(54) **Injectable compositions containing 25-cyclohexyl-avermectin B1.**

(30) Priority : **11.04.89 GB 8908071**

(43) Date of publication of application :
24.10.90 Bulletin 90/43

(45) Publication of the grant of the patent :
12.08.92 Bulletin 92/33

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(56) References cited :
**EP-A- 0 285 561
FR-A- 2 570 390
GB-A- 2 176 182**

(73) Proprietor : **Pfizer Limited
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)**

(84) **GB**
Proprietor : **PFIZER INC.
235 East 42nd Street
New York, N.Y. 10017 (US)**

(84) **BE CH DE DK ES FR GR IT LI LU NL SE AT**


(72) Inventor : **Wicks, Stephen Richard, Dr.
8 Goldfinch Close
Broomfield, Herne Bay, Kent (GB)**
Inventor : **Davison, Edward, Mr.
45 Leicester Avenue
Cliftonville, Margate, Kent (GB)**

(74) Representative : **Wood, David John et al
PFIZER LIMITED, Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)**

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention concerns the preparation of parenteral formulations of the compound known as 25-cyclohexyl-avermectin B1 of formula (I).



This compound is a member of the avermectin family, described and claimed in EP-A-0214731. The avermectins are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides and acaricides.

Antiparasitic agents are most conveniently administered to animals by using parenteral, subcutaneous or intramuscular formulations. Water is generally a convenient liquid for injection, but avermectins have a very low solubility in water and simple aqueous solutions are too dilute to be usable. Certain avermectins can be solubilized in water using surface active agents as solubilisers and suitable organic co-solvents to form a micellar solution as described in US Patent 4389397. However, these formulations do not provide doses of active compounds sufficient to remove satisfactorily both internal and external parasites of animals.

EP-A-146414 describes co-solvent solutions of avermectins, in a mixture of glycerol formal and propylene glycol or in propylene glycol containing a minor amount of water, for parenteral use. However, propylene glycol is known to cause irritation on subcutaneous or intramuscular injection. Additionally, minor amounts of water in these formulations may cause hydrolytic degradation of the avermectin.

Such formulations, which comprise water-miscible organic solvents for the avermectin, tend to produce unwanted local precipitation of the avermectin at the injection site. This may result in irritation and swelling at the injection site and in inefficient and inconsistent antiparasitic efficacy.

Indeed, the commercially available antiparasitic agent, "Ivomec injectable for cattle", a co-solvent formulation or an avermectin known as ivermectin, is only suitable for subcutaneous use and may cause irritation and swelling at the injection site.

An alternative method of providing an injectable solution of an avermectin is to dissolve the avermectin in a pharmaceutically acceptable oil. The use of arachis (peanut) and cottonseed oils, and also ethyl oleate, as solvents for certain avermectins is disclosed in GB-A-2166436. However, arachis oil and cottonseed oil do not provide a solution having at least a 1% w/v concentration of compound 1, as is generally required for a veterinary product. Veterinary formulations are commonly used or stored on farms at low temperatures, down to 4°C or even lower, and even if the avermectin is sufficiently soluble in the oil at normal room temperature it may precipitate or form a supersaturated solution, on exposure to cold conditions and thus become unusable. Pure ethyl oleate, and mixtures of oils containing a major proportion of ethyl oleate, attack certain plastics or rubber components of commonly used veterinary syringes to an unacceptable extent.

EP-A-285561 mentions pure sesame oil as a possible solvent for a different group of compounds, the milbemycins. In comparative viscosity and syringeability studies it has been found that pure sesame oil has a viscosity which is too high to allow its use as a solvent for injection using conventional veterinary syringe equipment. For this reason, pure sesame oil cannot be used as an injectable solvent under practical field con-

ditions.

The present invention is intended to provide a parenteral formulation for compound (I) which is effective against both internal and external parasites, is well tolerated by animals on both subcutaneous and intramuscular administration and is compatible with conventional injection equipment.

According to the invention, there is provided a solution of 25-cyclohexyl-avermectin B1, compound (I), in a solvent consisting of from 50 to 95% by volume of sesame oil with the remainder being ethyl oleate.

The preferred solvent mixture consists of from 75 to 90% of sesame oil by volume with the remainder being ethyl oleate.

The preferred content of avermectin for subcutaneous or intramuscular injection is from 1 to 30 mg/ml, most preferably about 10 mg/ml.

The formulations according to the invention are monophasic solutions and are effective in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting domestic animals and poultry. The compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various parasites which can infect humans including gastro-intestinal parasites such as Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filarial worms and the extra intestinal stages of Strongyloides and Trichinella.

The formulations of the invention are also of value in treating ectoparasite infections including in particular anthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect cattle and horses.

It has been found, unexpectedly, that formulations according to the invention show properties which are superior to the prior art formulations mentioned above, in that they show little or no irritation at the injection site when administered to animals by subcutaneous or intramuscular injection, are suitable for use in commonly used standard syringes, and give consistent antiparasitic efficacy.

A further advantage of the solutions of the invention is that, as the formulation vehicle contains esters of unsaturated acids, the avermectin is protected from air oxidation during prolonged storage.

The solutions of the invention may be prepared simply by dissolving compound (I) in the sesame oil ethyl oleate mixture and sterilising and packaging for administration in a conventional manner.

Formulations according to the invention are described by way of illustration in the following Examples.

EXAMPLES

Solutions of 25-cyclohexyl-avermectin B1 in the oil formulations were made and tested by the methods given below.

EXAMPLE 1

The following ingredients were used to prepare an injectable solution containing 10 mg of compound I in 1 ml of a nominal 90/10 mixture of sesame oil and ethyl oleate:

Compound I	10 mg
Ethyl oleate	0.1 ml
Sesame oil	to 1.0 ml

The ethyl oleate and sesame oil were mixed and heated to 80°C, whilst purging with nitrogen. Compound I is then added to the hot oils until dissolved and the resulting solution rapidly cooled and the volume adjusted to 1 ml with sesame oil, if required. This final solution was sterilised by membrane filtration and packaged aseptically.

EXAMPLE 2

Using the method of example 1, the following ingredients were used to prepare an injectable solution containing 10 mg of compound I in 1 ml of a nominal 50/50 mixture of sesame oil and ethyl oleate:

Compound I	10 mg
Ethyl oleate	0.5 ml
Sesame oil	to 1.0 ml

EXAMPLE 3

Using the method of example 1, the following ingredients were used to prepare an injectable solution containing 10 mg of compound I in 1 ml of a nominal 75/25 mixture of sesame oil and ethyl oleate:

5	Compound I	10 mg
	Ethyl oleate	0.25 ml
	Sesame oil	to 1.0 ml

EXAMPLE 4

10

The efficacy of compound I against ectoparasites was determined using a modification of the method described by L G Cramer *et al.*, in *Vet. Record*, (1988), 122, 611-612.

Compound I was administered to two groups of cattle by subcutaneous injection at a dose of 200µg/kg on day 0. Group A received compound I in an aqueous micelle formulation according to US-A-4389397 containing 2.5
15 mg of compound I, 120 mg of Tween 80 (Registered Trade Mark), 200 mg of glycerol formal, about 10 mg of benzyl alcohol and the remainder water per ml of formulation. Group B were treated with compound I in the formulation of example 1. The treated groups, together with a control for each treatment were then seeded with *Boophilus microplus* larvae on days 0, 2 and 4 and the ticks allowed to develop into adults. Resulting engorged adult female ticks were collected between days 21 and 32 and the mean daily counts recorded as shown in
20 Table 1.

25

30

35

40

45

50

55

Table 1Mean Daily counts of female B.microplus ticks collected

5

		Micelle	Untreated	Formulation	Untreated
	<u>Day</u>	<u>Formulation</u>	<u>Control</u>	<u>Example 1</u>	<u>Control</u>
10	21	0	287	0	0
	22	0	651	0	324
15	23	0	879	0	996
	24	0	753	0	1507
20	25	16	554	0	663
	26	76	267	0	852
	27	85	48	0	329
25	28	36	10	8	35
	29	28	5	15	19
30	30	16	0	3	1
	31	0	0	3	1
	32	0	0	1	0
35		—	—	—	—
	Totals	<u>257</u>	<u>3454</u>	<u>30</u>	<u>4727</u>

40

Treatment with formulation example 1 both delayed the production of adult female ticks and resulted in fewer ticks collected.

EXAMPLE 5

45

The toleration of avermectin formulations was assessed following injection into the semimembraneous muscle of cattle. Animals were humanely sacrificed at 7 and 14 days post-treatment and the injection sites, with surrounding tissue, removed. Tissues were examined for gross pathology and injection site lesions were evaluated using the scoring system described below.

50

0 = Normal, no visible lesion

1 = Light scar

2 = Heavy scar

3 = Encapsulated debris < 1.0cm³

4 = Encapsulated debris > 1.0 < 2.5cm³

55

5 = Encapsulated debris > 2.5cm³

Scores 0, 1 and 2 are considered acceptable. Scores greater than 2 have encapsulated debris. Compound I in formulations of examples 1 and 2 was administered to cattle by intramuscular injection at a dose of 200µg/kg. Injection site toleration was compared with that of the co-solvent formulation of the antiparasitic

agent, ivermectin (Trademark; Ivomec for cattle) given at the same dose and by the same route.

Table 2

Comparison of intramuscular injection site toleration scores

<u>Treatment</u>	<u>Day</u>	<u>Number of Animals</u>	<u>Average Score</u>
Formulation	7	5	0.4
example 1	14	10	0.0
Formulation	7	5	0.4
example 2	14	10	0.0
Ivomec	7	4	3.75
	14	8	2.75

Compound I in formulation examples 1 and 2, was well tolerated with only a few minor lesions at 7 days post-injection; resolving completely by 14 days. In contrast, Ivomec given by intramuscular injection was poorly tolerated at 7 days with encapsulated debris still visible 14 days post-injection.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. A solution of 25-cyclohexyl-ivermectin B1 in a solvent consisting of from 50 to 95% by volume of sesame oil with the remainder being ethyl oleate.

2. A solution according to claim 1, in which the solvent contains from 75% to 90% by volume of sesame oil with the remainder being ethyl oleate.

3. A solution according to claim 1 or 2, containing from 1 to 30 mg/ml of 25-cyclohexyl-ivermectin B1.

4. A solution according to claim 3, containing about 10 mg/ml of 25-cyclohexyl-ivermectin B1.

5. A solution according to any preceding claim, for subcutaneous or intramuscular injection into animals.

6. A solution according to any one of claim 1 to 4, for treating parasitic infections in animals.

7. A method of making a solution of 25-cyclohexyl-ivermectin B1 which comprises dissolving 25-cyclohexyl-ivermectin B1 in a solvent consisting of from 50 to 95% by volume of sesame oil with the remainder being ethyl oleate.

8. A method according to claim 7, in which the solvent contains from 75% to 90% by volume of sesame oil with the remainder being ethyl oleate.

9. A method according to claim 7 or 8, in which the solution formed contains from 1 to 30 mg/ml of 25-cyclohexyl-ivermectin B1.

Claims for the following Contracting States : ES, GR

1. A method for making a solution of 25-cyclohexyl-ivermectin B1 which comprises dissolving 25-cyclohexyl-ivermectin B1 in a solvent consisting of from 50 to 95% by volume of sesame oil with the remainder being ethyl oleate.

2. A method according to claim 1, in which the solvent contains from 75% to 90% by volume of sesame oil with the remainder being ethyl oleate.

3. A method according to claim 1 or 2, in which the solution formed contains from 1 to 30 mg/ml of 25-cyclohexyl-ivermectin B1.

5 Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Lösung von 25-Cyclohexyl-ivermectin B1 in einem Lösungsmittel, das aus 50 bis 95 Vol.-% Sesamöl besteht, wobei der Rest Ethyloleat ist.
2. Lösung nach Anspruch 1, in welcher das Lösungsmittel 75 bis 90 Vol.-% Sesamöl enthält, wobei der Rest Ethyloleat ist.
3. Lösung nach Anspruch 1 oder 2, die 1 bis 30 mg/ml 25-Cyclohexyl-ivermectin B1 enthält.
4. Lösung nach Anspruch 3, die etwa 10 mg/ml 25-Cyclohexyl-ivermectin B1 enthält.
5. Lösung nach irgendeinem vorhergehenden Anspruch zur subkutanen oder intramuskulären Injektion bei Tieren.
6. Lösung nach irgendeinem der Ansprüche 1 bis 4 zur Behandlung von parasitären Infektionen bei Tieren.
7. Verfahren zur Herstellung einer Lösung von 25-Cyclohexyl-ivermectin B1, das das Lösen von 25-Cyclohexyl-ivermectin B1 in einem Lösungsmittel umfaßt, das aus 50 bis 95 Vol.-% Sesamöl besteht, wobei der Rest Ethyloleat ist.
8. Verfahren nach Anspruch 7, in welchem das Lösungsmittel 75 bis 90 Vol.-% Sesamöl enthält, wobei der Rest Ethyloleat ist.
9. Verfahren nach Anspruch 7 oder 8, in welchem die gebildete Lösung 1 bis 30 mg/ml 25-Cyclohexyl-ivermectin B1 enthält.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer Lösung von 25-Cyclohexyl-ivermectin B1, umfassend das Lösen von 25-Cyclohexyl-ivermectin B1 in einem Lösungsmittel, das aus 50 bis 95 Vol.-% Sesamöl besteht, wobei der Rest Ethyloleat ist.
2. Verfahren nach Anspruch 1, in welchem das Lösungsmittel 75 bis 90 Vol.-% Sesamöl enthält, wobei der Rest Ethyloleat ist.
3. Verfahren nach Anspruch 1 oder 2, in welchem die gebildete Lösung 1 bis 30 mg/ml 25-Cyclohexyl-ivermectin B1 enthält.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Solution de 25-cyclohexyl-ivermectine B1 dans un solvant formé de 50 à 95% en volume d'huile de sésame, le complément étant de l'oléate d'éthyle.
2. Solution selon la revendication 1, dans laquelle le solvant renferme de 75% à 90% en volume d'huile de sésame, le complément étant de l'oléate d'éthyle.
3. Solution selon la revendication 1 ou 2, contenant de 1 à 30 mg/ml de 25-cyclohexyl-ivermectine B1.
4. Solution selon la revendication 3, contenant environ 10 mg/ml de 25-cyclohexyl-ivermectine B1.
5. Solution selon l'une quelconque des revendications précédentes, pour l'injection sous-cutanée ou intramusculaire chez l'animal.
6. Solution selon l'une quelconque des revendications 1 à 4, pour le traitement des infections parasitaires chez l'animal.
7. Procédé de fabrication d'une solution de 25-cyclohexyl-ivermectine B1 qui consiste à dissoudre la 25-cyclohexyl-ivermectine B1 dans un solvant formé de 50 à 95% en volume d'huile de sésame, le complément étant de l'oléate d'éthyle.
8. Procédé selon la revendication 7, dans lequel le solvant renferme de 75% à 90% en volume d'huile de sésame, le complément étant de l'oléate d'éthyle.
9. Procédé selon la revendication 7 ou 8, dans lequel la solution formée contient de 1 à 30 mg/ml de 25-cyclohexyl-ivermectine B1.

Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de fabrication d'une solution de 25-cyclohexyl-avermectine B1 qui consiste à dissoudre la 25-cyclohexyl-avermectine B1 dans un solvant formé de 50 à 95% en volume d'huile de sésame, le complément étant de l'oléate d'éthyle.

2. Procédé selon la revendication 1, dans lequel le solvant renferme de 75% à 90% en volume d'huile de sésame, le complément étant de l'oléate d'éthyle.

3. Procédé selon la revendication 1 ou 2, dans lequel la solution formée contient de 1 à 30 mg/ml de 25-cyclohexyl-avermectine B1.

REGISTER ENTRY FOR EP0393890

European Application No EP90303716.6 filing date 06.04.1990

Priority claimed:

11.04.1989 in United Kingdom - doc: 8908071

Designated States BE CH DE DK ES FR GB GR IT LI LU NL SE AT

Title INJECTABLE COMPOSITIONS CONTAINING 25-CYCLOHEXYL-AVERMECTIN B1.

Applicant/Proprietor

PFIZER LIMITED, Ramsgate Road, Sandwich Kent CT13 9NJ, United Kingdom

[ADP No. 50601020001]

Inventors

DR. STEPHEN RICHARD WICKS, 8 Goldfinch Close, Broomfield, Herne Bay, Kent,
United Kingdom [ADP No. 57922288001]

MR. EDWARD DAVISON, 45 Leicester Avenue, Cliftonville, Margate, Kent,
United Kingdom [ADP No. 57922296001]

Classified to

A61K

Address for Service

DAVID JOHN WOOD, PFIZER LIMITED, Ramsgate Road, Sandwich, Kent CT13 9NJ,
United Kingdom [ADP No. 50572098001]

EPO Representative

DAVID JOHN WOOD, PFIZER LIMITED, Ramsgate Road, Sandwich, Kent CT13 9NJ,
United Kingdom [ADP No. 50572098001]

Publication No EP0393890 dated 24.10.1990

Publication in English

Examination requested 14.04.1990

Patent Granted with effect from 12.08.1992 (Section 25(1)) with title
INJECTABLE COMPOSITIONS CONTAINING 25-CYCLOHEXYL-AVERMECTIN B1.

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

18/11/93 15:58:33
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER EP0393890

PROPRIETOR(S)

Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ, United Kingdom

DATE FILED 06.04.1990

DATE GRANTED 12.08.1992

DATE NEXT RENEWAL DUE 06.04.1994

DATE NOT IN FORCE

DATE OF LAST RENEWAL

YEAR OF LAST RENEWAL 00

STATUS PATENT IN FORCE